Publicaciones en colaboración con investigadores/as de Harvard Medical School (28)

2024

  1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

2023

  1. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

    Haematologica, Vol. 108, Núm. 11, pp. 2894-2912

  2. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

  3. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392

2022

  1. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

    Haematologica, Vol. 107, Núm. 10, pp. 2408-2417

  2. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

    Cancer Cell, Vol. 40, Núm. 11, pp. 1358-1373.e8

  3. Melflufen for the treatment of multiple myeloma

    Expert Review of Clinical Pharmacology

  4. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  5. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

  6. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  7. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response

    American Journal of Hematology

  2. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507

  3. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

  4. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

  3. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies

    Haematologica, Vol. 105, Núm. 2, pp. 468-477

  4. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

  5. Melflufen: A peptide–drug conjugate for the treatment of multiple myeloma

    Journal of Clinical Medicine, Vol. 9, Núm. 10, pp. 1-16